Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head and neck squamous cell carcinoma, according to new phase III trial data.

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs), but that was not the case. Still, according to researchers led by Deanna ...

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.